Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xenogen (XGEN) -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (44)	8/14/2006 12:19:47 PM
From: tuck	Respond to of 45

Deal done last Wednesday. XGEN last traded for $2.51. Shareholders have those warrants, but I'm still happy to have bailed where I did. From CALP's 2Q PR (Aug 9th): >>Caliper announced that both Caliper's and Xenogen Corporation's (Nasdaq: XGEN - News) stockholders have approved the acquisition of Xenogen by Caliper, and that the acquisition was completed as of today. The combined company, which will continue to be called Caliper Life Sciences, has assembled a leading portfolio of microfluidics, liquid handling, and imaging technologies that provide life science researchers with enabling tools to enhance the clinical relevance of their experimentation. "We are very pleased to complete the Xenogen acquisition, which will further enable Caliper to aggressively pursue critical path issues of drug discovery and development by focusing on key therapeutic areas and improving the correlation between in vitro and in vivo experimental data," continued Mr. Hrusovsky. "The integration of the two companies is off to a fast start as we begin to tap our strategic customer relationships and leverage our infrastructure to drive increased penetration of Xenogen's imaging technology into commercial accounts. Closing of the acquisition comes after a strong second quarter for Xenogen, in which Xenogen recorded revenues of $11.2 million, driven principally by 35% growth in IVIS molecular imaging system sales, compared to Xenogen's sales in the second quarter of 2005."<< XGEN had a better quarter, too, but the legal issue may come back and bite CALP. I reiterate my position that they will cross license, but perhaps not on terms as favorable as I at first thought. My Mom still owns some CALP, so I wish both well. Cheers, Tuck